Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.
|Articles|May 1, 2016
May 2016: The Future of Hub Services: Higher Touch, Less Complexity
Author(s)Triplefin
As competition in a diversifying specialty drug business rises to fiver pitch, manufacturers are seeking new ways to differentiate the product servicing model to help their brands stand out. Triplefin's Hub-Lite™ program is adapting to these new expectations with a customized set of services geared to specialty's biggest growth segment: mid-range therapies with higher price tags than traditional retail pharmacy but significantly lower than high-end specialty pharma.
Advertisement
Advertisement
Related to this article
As established gains in personalized and targeted therapy have enabled increasingly precise approaches to disease, novel technologies are expanding what is possible while creating new challenges for drug developers.
TRexBio and Retension Pharmaceuticals priced IPOs, raising a combined $161.7 million to advance their immunology and hypertension pipelines ahead of their Nasdaq debuts.
The FDA approved Tecentriq plus chemotherapy for stage III dMMR colon cancer, Roche’s 12th US indication for the immunotherapy.
Pharma's chain of custody model is migrating into food and consumer goods — and becoming a cross-industry differentiator.
Ultragenyx sells a rare pediatric disease priority review voucher for $210 million, Viatris acquires Pacira BioSciences for $1.65 billion, and Peter Young surveys a steadying biopharma outlook.
Improved financing conditions and accelerating M&A are creating new opportunities, but policy uncertainty, patent expirations and persistent funding pressures continue to shape the outlook for pharma and biotech.
Exploring the emergence of agentic ecosystems in transforming data accessibility and ensuring reliable answers reach the people making decisions while there is still a choice to make.
Advertisement
Advertisement
Trending on PharmExec
1
Viatris Acquires Pacira BioSciences for $1.65 Billion
2
Ultragenyx to Sell Rare Pediatric Disease Priority Review Voucher for $210 Million
3
Roundup: TRexBio & Retension Pharmaceuticals Announce IPO Pricing
4
FDA Approves Tecentriq for Stage III dMMR Colon Cancer
5